Gresser I, Maury C, Belardelli F, Maunoury M T, Machover D
Laboratory of Viral Oncology, Institut de Recherches Scientifiques sur le Cancer, Villejuif, France.
J Natl Cancer Inst. 1988 Mar 16;80(2):126-31. doi: 10.1093/jnci/80.2.126.
DBA/2 mice received an iv injection of 2 X 10(6) Friend erythroleukemia cells (FLCs; approximately equal to 4 X 10(5) lethal dose50), which multiplied rapidly in the liver and spleen and killed all untreated or control treated mice between 7 and 12 days. Daily interferon (IFN) treatment resulted in a very marked increase in survival time and apparent cure of 4 of 22 tumor-inoculated mice. In contrast, treatment of tumor-injected (iv) mice with cyclophosphamide, 5-fluorouracil, and methotrexate increased survival time by only a few days; and treatment of mice with cisplatin, vincristine, doxorubicin, bleomycin, or etoposide was ineffective. However, when FLCs were injected ip, both cytostatic drugs and IFN exerted an antitumor effect. We conclude that IFN alpha/beta was particularly effective in inhibiting the development of liver and spleen metastases and in increasing mouse survival time after iv inoculation of FLCs.
DBA/2小鼠接受静脉注射2×10⁶个弗氏红白血病细胞（FLCs；约等于4×10⁵个致死剂量50），这些细胞在肝脏和脾脏中迅速增殖，并在7至12天内杀死所有未治疗或接受对照治疗的小鼠。每日干扰素（IFN）治疗导致存活时间显著延长，22只接种肿瘤的小鼠中有4只明显治愈。相比之下，用环磷酰胺、5-氟尿嘧啶和甲氨蝶呤治疗肿瘤注射（静脉注射）小鼠仅使存活时间延长几天；而用顺铂、长春新碱、阿霉素、博来霉素或依托泊苷治疗小鼠则无效。然而，当通过腹腔注射接种FLCs时，细胞抑制药物和IFN均发挥抗肿瘤作用。我们得出结论，在静脉接种FLCs后，α/β干扰素在抑制肝脾转移的发生以及延长小鼠存活时间方面特别有效。
